Form 4: VolitionRx CFO Awarded 202,000 RSUs in Lieu of Cash

VolitionRx's Chief Financial Officer, Terig Hughes, was awarded 202,000 restricted stock units under the company's 2024 Stock Incentive Plan.

Summary

• Terig Hughes, Chief Financial Officer of VolitionRx Ltd (VNRX), was awarded 202,000 restricted stock units (RSUs) on February 26, 2026.
• The RSUs were granted under the Issuer's 2024 Stock Incentive Plan and were in lieu of cash compensation that would otherwise have been owed to Mr. Hughes.
• The RSUs will be earned in twelve approximately equal monthly installments, commencing on March 1, 2026.
• Once earned, the RSUs are subject to additional time-based vesting in a single installment on February 26, 2027.
• Vesting is generally contingent upon Mr. Hughes' continued service to the company throughout each applicable earning and vesting date.
• Upon vesting and settlement, Mr. Hughes will receive shares of common stock equal to the number of earned and vested RSUs.
• Following this transaction, Mr. Hughes beneficially owns 684,970 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the alignment of executive incentives with shareholder interests and the retention aspect. The potential for future dilution is a minor consideration given the size of the award relative to the company's overall outstanding shares.

Positives

• The RSU award aligns the Chief Financial Officer's long-term interests with those of shareholders, as his compensation is tied to the company's stock performance.
• Granting RSUs in lieu of cash compensation helps conserve the company's cash reserves, which can be beneficial for operational liquidity or other strategic investments.
• The multi-year vesting schedule (earning through March 2027) acts as a retention mechanism for a key executive.

Negatives

• The issuance of 202,000 RSUs, once vested and settled into common stock, represents potential future dilution for existing shareholders.
• Tying a significant portion of executive compensation to stock performance can expose the executive's personal wealth to market volatility.

Risks

• The RSUs are subject to continued service by the reporting person throughout each applicable earning and vesting date, meaning forfeiture if employment ceases prematurely.

Future Outlook

The filing indicates a future commitment to executive compensation through equity, with RSUs earning monthly from March 1, 2026, and a final vesting date on February 26, 2027, contingent on continued service.

Industry Context

StockSavvy.ai notes that awarding restricted stock units (RSUs) to key executives is a common practice in the biotechnology and diagnostic industry, including companies like VolitionRx. This method of compensation is widely used to align management incentives with long-term shareholder value creation and to retain talent, particularly in sectors with high research and development costs and long product development cycles.

Comparison to Industry Standards

• The use of RSUs as a component of executive compensation is a standard practice across many industries, including life sciences, comparable to companies like Exact Sciences (EXAS) or Guardant Health (GH) which also utilize equity awards to incentivize and retain key personnel.
• The vesting schedule, with monthly earning and a final time-based vesting, is typical for such awards, designed to ensure continued service and long-term commitment from the executive.

Related Party Transactions

• The award of 202,000 restricted stock units to Terig Hughes, the Chief Financial Officer, constitutes a related party transaction as it involves compensation between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon RSU vesting and settlement, but also benefit from increased alignment of executive interests with long-term company performance.
• Employees (specifically the CFO): Compensation structure is now more heavily weighted towards equity, linking personal wealth to company stock performance and providing a strong incentive for continued service.

Next Steps

• The RSUs will begin earning in approximately equal monthly installments starting March 1, 2026.
• The RSUs will be subject to additional time-based vesting in a single installment on February 26, 2027.

Key Dates

Keywords

VolitionRx, VNRX, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Stock Incentive Plan, CFO, Equity Award